PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice.

[1]  S. Hwang,et al.  COX‐2/sEH dual inhibitor PTUPB alleviates bleomycin‐induced pulmonary fibrosis in mice via inhibiting senescence , 2020, The FEBS journal.

[2]  Ting Liu,et al.  Zinc-α2-glycoprotein 1 attenuates non-alcoholic fatty liver disease by negatively regulating tumour necrosis factor-α , 2019, World journal of gastroenterology.

[3]  Lixin Wei,et al.  BabaoDan attenuates high-fat diet-induced non-alcoholic fatty liver disease via activation of AMPK signaling , 2019, Cell & Bioscience.

[4]  Fang Wang,et al.  Compound C Protects Mice from HFD-Induced Obesity and Nonalcoholic Fatty Liver Disease , 2019, International journal of endocrinology.

[5]  Sui Huang,et al.  Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor , 2019, Proceedings of the National Academy of Sciences.

[6]  B. Hammock,et al.  Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders , 2019, Progress in Neurobiology.

[7]  W. Zhong,et al.  Inhibition of glycolysis alleviates lipopolysaccharide‐induced acute lung injury in a mouse model , 2018, Journal of cellular physiology.

[8]  G. Tiegs,et al.  NLRP3 Inflammasome and IL-33: Novel Players in Sterile Liver Inflammation , 2018, International journal of molecular sciences.

[9]  K. R. Ethiraj,et al.  Safer anti‐inflammatory therapy through dual COX‐2/5‐LOX inhibitors: A structure‐based approach , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  Xin-Hua Xiao,et al.  Zinc alpha2 glycoprotein protects against obesity-induced hepatic steatosis , 2018, International Journal of Obesity.

[11]  Xianqun Fan,et al.  Inhibition of Soluble Epoxide Hydrolase 2 Ameliorates Diabetic Keratopathy and Impaired Wound Healing in Mouse Corneas , 2018, Diabetes.

[12]  Jingjing Cai,et al.  Hepatic leukocyte immunoglobulin‐like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1‐TRAF6 pathway , 2018, Hepatology.

[13]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[14]  Di Chen,et al.  Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. , 2017, Journal of hepatology.

[15]  G. Kroemer,et al.  Bax Inhibitor-1 protects from Non-Alcoholic Steatohepatitis by limiting IRE 1 α signaling , 2018 .

[16]  R. Robertson,et al.  The COX-2/PGE2/EP3/Gi/o/cAMP/GSIS Pathway in the Islet: The Beat Goes On , 2017, Diabetes.

[17]  B. Hammock,et al.  Soluble Epoxide Hydrolase Inhibitor Attenuates Lipopolysaccharide-Induced Acute Lung Injury and Improves Survival in Mice , 2017, Shock.

[18]  S. Hwang,et al.  A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. , 2016, Prostaglandins & other lipid mediators.

[19]  Chunjiong Wang,et al.  Soluble epoxide hydrolase: A potential target for metabolic diseases , 2016, Journal of diabetes.

[20]  G. FitzGerald,et al.  Effects of selective COX-2 inhibition on allergen-induced bronchoconstriction and airway inflammation in asthma. , 2014, Journal of Allergy and Clinical Immunology.

[21]  O. Hammam,et al.  Pharmacological and antioxidant actions of garlic and.or onion in non-alcoholic fatty liver disease (NAFLD) in rats. , 2014, Journal of the Egyptian Society of Parasitology.

[22]  A. Wree,et al.  NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice , 2014, Hepatology.

[23]  G. Shulman,et al.  Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 Diabetes , 2014, Hepatology.

[24]  P. Kubes,et al.  Sterile inflammation in the liver. , 2012, Gastroenterology.

[25]  Richard A. Flavell,et al.  Inflammasomes in health and disease , 2012, Nature.

[26]  Richard A. Flavell,et al.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity , 2012, Nature.

[27]  S. Hwang,et al.  Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. , 2011, Journal of medicinal chemistry.

[28]  E. J. Belin de Chantemèle,et al.  Cyclooxygenase-2 Inhibition Restored Endothelium-Mediated Relaxation in Old Obese Zucker Rat Mesenteric Arteries , 2010, Front. Physio..

[29]  S. Harrison,et al.  Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection , 2010, Hepatology.

[30]  P. Newsome,et al.  Pathogenesis of non-alcoholic fatty liver disease , 2009, QJM : monthly journal of the Association of Physicians.

[31]  J. Tschopp,et al.  The Inflammasomes , 2010, Cell.

[32]  G. Kim.  Renal Effects of Prostaglandins and Cyclooxygenase-2 Inhibitors , 2008, Electrolyte & blood pressure : E & BP.

[33]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[34]  B. Rehermann,et al.  The liver as an immunological organ , 2004 .

[35]  H. Cortez‐Pinto,et al.  Non-alcoholic steatohepatitis: from cell biology to clinical practice. , 2006, Journal of hepatology.

[36]  J. Imig,et al.  CYP450, COX-2 and Obesity Related Renal Damage , 2005, Toxicology mechanisms and methods.

[37]  M. Feldmann,et al.  TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases , 2003, Nature Medicine.

[38]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.